Is Perspective Therapeutics Stock a Good Investment?
Perspective Therapeutics Investment Advice | CATX |
- Examine Perspective Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Perspective Therapeutics' leadership team and their track record. Good management can help Perspective Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Perspective Therapeutics' business and its evolving consumer preferences.
- Compare Perspective Therapeutics' performance and market position to its competitors. Analyze how Perspective Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Perspective Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Perspective Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Perspective Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Perspective Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Perspective Therapeutics Stock
Researching Perspective Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 20.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.65. Some equities with similar Price to Book (P/B) outperform the market in the long run. Perspective Therapeutics recorded a loss per share of 1.33. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 17th of June 2024.
To determine if Perspective Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Perspective Therapeutics' research are outlined below:
| Perspective Therapeutics generated a negative expected return over the last 90 days | |
| Perspective Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 1.43 M. Net Loss for the year was (46.51 M) with profit before overhead, payroll, taxes, and interest of 1.56 M. | |
| Perspective Therapeutics generates negative cash flow from operations | |
| Perspective Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 82.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from businesswire.com: Space-based Intelligence, Surveillance, and Reconnaissance Research Report 2024 Explore the Role of AI, Advanced Analytics, and Modular Satellite Constellations in Enhancing Capabilities - ResearchAndMarkets.com |
Perspective Therapeutics Quarterly Good Will |
|
Perspective Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Perspective Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Perspective Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Perspective Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Perspective Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-11 | 2023-06-30 | -0.03 | -0.04 | -0.01 | 33 | ||
2023-02-16 | 2022-12-31 | -0.01 | -0.02 | -0.01 | 100 | ||
2021-11-10 | 2021-09-30 | -0.01 | -0.02 | -0.01 | 100 | ||
2020-09-17 | 2020-06-30 | -0.01 | -0.02 | -0.01 | 100 | ||
2019-11-12 | 2019-09-30 | -0.02 | -0.01 | 0.01 | 50 | ||
2018-09-25 | 2018-06-30 | -0.03 | -0.04 | -0.01 | 33 | ||
2018-02-08 | 2017-12-31 | -0.02 | -0.03 | -0.01 | 50 | ||
2017-05-10 | 2017-03-31 | -0.01 | -0.02 | -0.01 | 100 |
Perspective Therapeutics Target Price Consensus
Perspective target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Perspective Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 10 | Strong Buy |
Most Perspective analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Perspective stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Perspective Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationPerspective Therapeutics Target Price Projection
Perspective Therapeutics' current and average target prices are 3.43 and 16.15, respectively. The current price of Perspective Therapeutics is the price at which Perspective Therapeutics is currently trading. On the other hand, Perspective Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Perspective Therapeutics Market Quote on 18th of January 2025
Target Price
Analyst Consensus On Perspective Therapeutics Target Price
Perspective Therapeutics Analyst Ratings
Perspective Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Perspective Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Perspective Therapeutics' financials, market performance, and future outlook by experienced professionals. Perspective Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Perspective Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 213.58 M.Market Cap |
|
Perspective Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.28) | (2.16) | |
| Return On Capital Employed | (0.57) | (0.54) | |
| Return On Assets | (0.55) | (0.52) | |
| Return On Equity | (0.71) | (0.75) |
Determining Perspective Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Perspective Therapeutics is a good buy. For example, gross profit margin measures Perspective Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Perspective Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Perspective Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Perspective Therapeutics. Check Perspective Therapeutics' Beneish M Score to see the likelihood of Perspective Therapeutics' management manipulating its earnings.
Evaluate Perspective Therapeutics' management efficiency
Perspective Therapeutics has return on total asset (ROA) of (0.1435) % which means that it has lost $0.1435 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2702) %, meaning that it created substantial loss on money invested by shareholders. Perspective Therapeutics' management efficiency ratios could be used to measure how well Perspective Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -2.16 in 2025. Return On Capital Employed is likely to rise to -0.54 in 2025. At this time, Perspective Therapeutics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 97.9 M in 2025, whereas Total Current Assets are likely to drop slightly above 14.5 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.23 | 3.07 | |
| Tangible Book Value Per Share | 0.03 | 0.03 | |
| Enterprise Value Over EBITDA | (2.90) | (2.76) | |
| Price Book Value Ratio | 1.29 | 1.22 | |
| Enterprise Value Multiple | (2.90) | (2.76) | |
| Price Fair Value | 1.29 | 1.22 | |
| Enterprise Value | 90.8 M | 86.3 M |
Understanding the operational decisions made by Perspective Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 1.467 |
Basic technical analysis of Perspective Stock
As of the 18th of January 2025, Perspective Therapeutics holds the Variance of 70.14, coefficient of variation of (513.50), and Risk Adjusted Performance of (0.15). Perspective Therapeutics technical analysis gives you tools to exploit past prices in attempt to determine a pattern that determines the direction of the company's future prices.Perspective Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Perspective Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Perspective Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Perspective Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand Perspective Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Perspective Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.15) | |||
| Market Risk Adjusted Performance | 2.28 | |||
| Mean Deviation | 4.97 | |||
| Coefficient Of Variation | (513.50) | |||
| Standard Deviation | 8.37 | |||
| Variance | 70.14 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (1.63) | |||
| Total Risk Alpha | (1.84) | |||
| Treynor Ratio | 2.27 | |||
| Maximum Drawdown | 55.49 | |||
| Value At Risk | (11.66) | |||
| Potential Upside | 6.34 | |||
| Skewness | (2.95) | |||
| Kurtosis | 19.1 |
| Risk Adjusted Performance | (0.15) | |||
| Market Risk Adjusted Performance | 2.28 | |||
| Mean Deviation | 4.97 | |||
| Coefficient Of Variation | (513.50) | |||
| Standard Deviation | 8.37 | |||
| Variance | 70.14 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (1.63) | |||
| Total Risk Alpha | (1.84) | |||
| Treynor Ratio | 2.27 | |||
| Maximum Drawdown | 55.49 | |||
| Value At Risk | (11.66) | |||
| Potential Upside | 6.34 | |||
| Skewness | (2.95) | |||
| Kurtosis | 19.1 |
Consider Perspective Therapeutics' intraday indicators
Perspective Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Perspective Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Perspective Therapeutics Corporate Filings
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 7th of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
F4 | 6th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Perspective Stock media impact
Far too much social signal, news, headlines, and media speculation about Perspective Therapeutics that are available to investors today. That information is available publicly through Perspective media outlets and privately through word of mouth or via Perspective internal channels. However, regardless of the origin, that massive amount of Perspective data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Perspective Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Perspective Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Perspective Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Perspective Therapeutics alpha.
Perspective Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Perspective Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Perspective Therapeutics Corporate Management
| Annie Cheng | Vice Relations | Profile | |
| Andrew Bright | Executive Brachytherapy | Profile | |
| Michael Schultz | Chief Officer | Profile | |
| Steve Keefe | Senior Development | Profile | |
| PGradDip BA | Chief Officer | Profile | |
| Jonathan Hunt | Chief Officer | Profile |
Additional Tools for Perspective Stock Analysis
When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.